Fox Chase/Stanford Study: Radiation Therapy Effective in Treating Younger Men with Early-Stage Prostate Cancer

OncologyONCOLOGY Vol 10 No 4
Volume 10
Issue 4

Researchers at two major medical centers have found that radiation therapy is just as successful as surgery in treating younger men with early-stage prostate cancer. Currently, men 60 years old or under with prostate cancer are far more likely to be treated with surgery than with radiation therapy.

Researchers at two major medical centers have found that radiationtherapy is just as successful as surgery in treating younger menwith early-stage prostate cancer. Currently, men 60 years oldor under with prostate cancer are far more likely to be treatedwith surgery than with radiation therapy.

The two studies were conducted at Fox Chase Cancer Center in Philadelphiaand Stanford University Medical Center, Stanford, California.Results were presented at the annual meeting of the American Societyfor Therapeutic Radiology and Oncology (ASTRO) in Miami Beach,Florida.

Fox Chase Study

In the Fox Chase study, cure rates were analyzed for 459 men withearly-stage prostate cancer treated only with radiation therapy.Those men under the age of 60 have done as well as the older menup to 5 years after treatment, according to radiation oncologistsDrs. Gerald Hanks and Gary Freedman, research team members.

Dr. Freedman said that, based on the study results, "radiationtherapy shouldn't be discounted as a treatment for early-stageprostate cancer simply because the patient is a younger man."

Nationwide, from 1984 to 1991 the number of men under the ageof 70 with early-stage prostate cancer undergoing surgery rosefrom 22% to 57%, while the number of men having radiation therapydeclined from 35% to 21%, according to Dr. Freedman. "Ourstudy adds to the body of evidence that radiation therapy offersan equal chance for cure as surgery in the treatment of early-stageprostate cancer."

Based on the results of the Fox Chase study, he added, "webelieve that men of any age can be offered various treatment optionsincluding radiation therapy."

Stanford Study

In the Stanford study, meanwhile, patients age 60 or younger withearly-stage prostate cancer who were treated with radiation alsodid as well--or better in many cases--than older men treated inthe same manner. Overall, 396 early-stage prostate cancer patients--110of them age 60 or under--were studied.

The study was based on an average follow-up of 18 years, accordingto radiation oncologist Dr. Joseph Poen, a research team member."Our study results contradict arguments that radiation therapyonly controls prostate cancer for a limited period of time,"he maintained.

Dr. Poen said that some physicians believe that younger men whowould normally have a life expectancy greater than 10 years requiresurgery for lasting control of the disease. As a result of thisbelief, most younger patients have been referred for radical prostatectomy.But the fact is, the Stanford study shows that radiation therapydoes have long-lasting positive results in treating early-stageprostate cancer, he said.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content